<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179621</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MDS-004</org_study_id>
    <secondary_id>2005-000454-73</secondary_id>
    <nct_id>NCT00179621</nct_id>
  </id_info>
  <brief_title>Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31] Cytogenetic Abnormality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of
      placebo in subjects with red blood cell (RBC) transfusion-dependent low- or
      intermediate-1-risk IPSS MDS associated with a deletion (del) 5q[31] cytogenetic abnormality.
      Study participants were randomized to one of the two treatment groups or to placebo and took
      the study drug for 16 weeks. At this timepoint, participants were evaluated for erythroid
      response. If participants did not achieve at least a minor erythroid response, they were
      discontinued from the Double-Blind phase and entered into the Open-Label phase. All erythroid
      responders at Week 16 were to continue in the Double-Blind phase for up to 52 weeks. For
      participants that were still responding at the end of Double-Blind phase, they could then
      rollover into the Open-Label phase for an additional two years. Participants could remain on
      study for up to a total of 3 years. All participants who discontinued from the study were
      followed every 4 months for overall survival and progression to acute myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MDS-004 was a multicenter, randomized, double-blind, placebo-controlled, 3-arm study of 2
      doses of lenalidomide versus placebo administered to RBC transfusion-dependent adults with
      low- or intermediate-1 risk MDS associated with a del 5q[31] cytogentetic abnormality.
      Potential participants that had a del 5q[31] cytogenetic abnormality plus other additional
      cytogenetic abnormalities were also eligible for enrollment. Transfusion-dependent anemia was
      defined as documentation that a participant with anemia due to MDS did not have any
      consecutive 56 days (8 weeks) that were RBC transfusion free during at least the 112 days (16
      weeks) prior to Day 1 of the Pre-Randomization Phase.

      This study was conducted in three phases:

        1. a Pre-Randomization Phase

        2. a Double-Blind Treatment Phase

        3. an Open-Label Extension Phase

      Potentially protocol-eligible participants entered the Pre-Randomization Phase and were
      evaluated for the inclusion and exclusion criteria for the Double-Blind Treatment Phase. The
      Pre-Randomization Phase was not to last for more than 56 days (8 weeks). When the
      participant's baseline RBC transfusion requirement was calculated, and it had been determined
      that all eligibility criteria had been met, the participant could be randomized for treatment
      in the Double-Blind Treatment Phase at the time of their next RBC transfusion. This RBC
      transfusion had to occur within 56 days of the participant's last previous RBC transfusion.

      Participants meeting eligibility criteria were randomized (1:1:1 ratio) to receive either
      lenalidomide 10 mg/day on days 1-21, lenalidomide 5 mg/day on days 1-28, or placebo on days
      1-28; all on a 28-day cycle. Randomization was performed using a validated interactive voice
      response system. Participants were stratified according to karyotype (IPSS karyotype score: 0
      vs &gt; 0; i.e., isolated del 5q[31] vs del 5q[31] plus ≥ 1 additional cytogenetic abnormality).
      A complete blood count (CBC), serum or plasma ferritin, and EPO levels were measured to
      determine baseline levels.

      Participants who achieved at least a minor erythroid response (i.e. 50% decrease in
      transfusion requirements) by week 16 could continue treatment in the Double-Blind phase for
      up to 52 weeks, unless there was evidence of erythroid relapse, disease progression, or
      unacceptable toxicity. Those who did not achieve at least a minor erythroid response by week
      16 were discontinued from the Double-Blind phase for lack of therapeutic efficacy, and
      unblinded and were potentially eligible for Open-Label treatment. All participants who
      completed the double-blind treatment phase (the first 52 weeks of the trial) without disease
      progression or erythroid relapse were unblinded and entered the Open-Label extension phase at
      their current lenalidomide dose. Participants in the placebo or lenalidomide 5 mg arms who
      failed to achieve at least a minor erythroid response by week 16 or who had an erythroid
      relapse could cross over to lenalidomide 5 mg or 10 mg, respectively, in the Open-Label
      Extension phase.

      Lenalidomide treatment could be continued in the Open-label Extension phase for up to 3 years
      (156 weeks) of total study participation. Participants with disease progression at any time
      and participants in the lenalidomide 10 mg group who did not achieve at least a minor
      erythroid response by week 16 were withdrawn from the study and were ineligible for
      Open-Label treatment.

      Serial measurements for efficacy and safety were performed every 28 days. In addition, CBCs
      were monitored weekly for the first 8 weeks, every 2 weeks for the next 8 weeks, and every 4
      weeks thereafter. Bone marrow aspirate (BMA) and standard cytogenetic studies were performed
      at baseline, weeks 12, week 24, and every 24 weeks thereafter and when clinically indicated
      for assessment of disease progression. BMAs were submitted for central pathology review and
      sent to a central cytogenetics laboratory for processing and review. All participants were
      followed for overall survival (OS) and progression to acute myeloid leukemia (AML).

      Lenalidomide or placebo dosing was reduced for dose-limiting toxicities according to the
      following dose reduction schedule:

        -  Lenalidomide 5 mg (starting dose)

             -  dose level −1 (5 mg every other day)

             -  dose level −2 (5 mg twice a week)

             -  dose level −3 (5 mg weekly)

        -  Lenalidomide 10 mg (starting dose)

             -  dose level −1 (5 mg daily)

             -  dose level −2 (5 mg every other day)

             -  dose level −3 (5 mg twice a week)

      Participants who could not tolerate dose level −3 discontinued treatment. For grade 4
      neutropenia, lenalidomide was required per protocol to be interrupted and resumed at a
      decreased dose level when the absolute neutrophil count (ANC) recovered to ≥ 500/μL. For
      grade 4 thrombocytopenia, lenalidomide was interrupted and then resumed at a decreased dose
      level when the platelet count recovered to: between ≥ 25,000/μL and &lt; 50,000/μL on at least 2
      occasions for ≥ 7 days; or ≥ 50,000 at any time, respectively. Prophylactic and therapeutic
      use of granulocyte colony-stimulating factors (G-CSF) or granulocyte macrophage
      colony-stimulating factors (GM-CSF) was allowed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for &gt;= 26 Weeks (182 Days)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days</measure>
    <time_frame>Baseline, up to 52 weeks</time_frame>
    <description>For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of &lt;100,000/mm^3 as an absolute increase of ≥30,000/mm^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm^3 but less than 30,000/mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</measure>
    <time_frame>up to week 52</time_frame>
    <description>A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase &lt;500/mm^3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) &lt;5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with &lt;5% blasts pretreatment with an on study blast increase of 50% which is now &gt;5% showed bone marrow progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimates of Overall Survival by Randomized Group</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Count of Deaths During Double-blind and Open-label by Randomized Group</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Count of participant deaths throughout the entire study and reported by the original treatment assignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL).
In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period</measure>
    <time_frame>up to week 52</time_frame>
    <description>Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching to active study arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 5 mg daily 28/28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 10 mg daily 21/28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide 5 mg</intervention_name>
    <description>Lenalidomide 5 mg daily 28/28 days</description>
    <arm_group_label>Lenalidomide 5 mg</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide 10 mg</intervention_name>
    <description>Lenalidomide 10 mg daily 21/28 days</description>
    <arm_group_label>Lenalidomide 10 mg</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, matching to active study drug arms</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must understand and voluntarily sign an informed consent form

          -  Age 18 years at the time of signing the informed consent form

          -  Documented diagnosis of myelodysplastic syndromes (MDS) that meets International
             Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and
             has an associated del 5q(31) cytogenetic abnormality

          -  Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days
             without a RBC transfusion within at least the immediate 112 days

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Women of childbearing potential must have a negative pregnancy test prior to inclusion

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Prior therapy with lenalidomide

          -  Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia
             (CMML)

          -  Prior &gt;= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology
             Criteria for AEs (CTCAE) (v 3.0)) allergic reaction to thalidomide

          -  Prior desquamating (blistering) rash while taking thalidomide

          -  Prior history of malignancy other than MDS (except basal cell or squamous cell
             carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been
             free of disease for &gt;3 years

          -  Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not
             commercially available) for the treatment of MDS within 28 days

          -  Less than 6 months since prior allogeneic bone marrow transplantation

          -  Less than 3 months since prior autologous bone marrow or stem cell transplantation

          -  Less than 28 days since prior myelosuppressive anticancer biologic therapy

          -  Recombinant human erythropoietin (rHuEPO) therapy received within 28 days

          -  Known human immunodeficiency virus (HIV-1) positivity

          -  Any serious medical condition or psychiatric illness that will prevent the subject
             from signing the informed consent form or will place the subject at unacceptable risk
             if he or she participates in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Backstrom, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ St-Jan Brugge AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Mont Godine</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 9</state>
        <zip>B.P.156 - 13272</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers Service des Maladies du Sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hematologie et Medicine interne</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Archet 1Hematologie Clinique</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Hematologie Clinique</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernhard Service Onco-Hematologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel Service d'Hematologie Clinique</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan, Place du Dr Baylac, Pavillon des Médecines</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan, Place du Dr. Baylac, Pavillion des Medecines</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Hematologie et Medecine interne</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Johannes Hospital</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pavia Division of Hematology</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6526 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologie Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SU/Sahlgrenska Section of Hematology &amp; Coagulation</name>
      <address>
        <city>Goteborg</city>
        <zip>SE 413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>S-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korolinska Institutet Department of Hematology</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales, Dept of Haematology</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leed General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3 EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital, Denmark Hill</name>
      <address>
        <city>London</city>
        <zip>SE 5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital and the Weatherall Institute of Molecular Medicine</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Fenaux, Pierre, Giagounidis, Aristotle, Selleslag, Dominik, Beyne-Rauzy, Odile, Mufti, Ghulam J, Mittelman, Moshe, Muus, Petra, te Boekhorst, Peter, Sanz, Guillermo, del Canizo, Consuelo, Guerci-Bresler, Agnes, Schlegelberger, Brigitte, Aul, Carlo, Kreipe, Hans, Goehring, Gudrun, Knight, Robert, Francis, John, Fu, Tommy, Hellstrom-Lindberg, Eva. RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). ASH Annual Meeting Abstracts 2009 114: 944.</citation>
  </results_reference>
  <results_reference>
    <citation>Fenaux, P., Giagounidis, A., Selleslag, D. L., Beyne-Rauzy, O., Mittelman, M., Muus, P., Knight, R. D., Fu, T., Hellstrom-Lindberg, E., The MDS-004 Len del(5q) Study Group. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. J Clin Oncol (Meeting Abstracts) 2010 28: 6598</citation>
  </results_reference>
  <results_reference>
    <citation>Fenaux, P., Giagounidis, A., Selleslag, D., Knight, R., Fu, T., Hellström-Lindberg, E. Effect of baseline EPO and prior erythropoiesis stimulating agents on RBC transfusion independence in Low-/Int-1-Risk MDS with del 5q treated with lenalidomide: A randomized phase 3 study (MDS-004). Haematologica 2010; 95[suppl.2]:125, abs. 0311.</citation>
  </results_reference>
  <results_reference>
    <citation>Brandenburg, N., Fu, T., Revicki, D., Knight, R., Muus, P., Fenaux, P. Impact of lenalidomide on health-related quality of life in patients with RBC transfusion-dependent low- or int-1-risk myelodysplastic syndromes with del 5q: a randomized Phase 3 study (MDS-004). Haematologica 2010; 95[suppl.2]:127, abs. 0316</citation>
  </results_reference>
  <results_reference>
    <citation>Fenaux, P., Giagounidis, A., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., Cazzola, M., Backstrom, J., Fu, T., Hellström-Lindberg, E. Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004). Blood ASH Annual Meeting Abstracts 2010 116:21 abs. 4027.</citation>
  </results_reference>
  <results_reference>
    <citation>Brandenburg, N., Yu, R., Revicki, D. Reliability and Validity of the FACT-AN In Patients with Low or Int-1-Risk Myelodysplastic Syndromes with Deletion 5q. Blood ASH Annual Meeting Abstracts 2010 116:21 abs. 3827.</citation>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 9, 2011</results_first_submitted>
  <results_first_submitted_qc>February 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2011</results_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jay Backstrom, MD, Vice President, Clinical Development MDS</name_title>
    <organization>Celgene Corporation</organization>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>transfusion dependent</keyword>
  <keyword>anaemia</keyword>
  <keyword>cytogenetic abnormality 5q-</keyword>
  <keyword>erythroid response</keyword>
  <keyword>leukaemia</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Celgene</keyword>
  <keyword>revlimid</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 263 potential participants were screened. Potentially protocol-eligible participants were then entered into the Pre-Randomization Phase (up to 56 days) to ensure eligibility criteria were met prior to entering the Double-Blind Phase. A total of 205 participants were randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matching to active study arms.</description>
        </group>
        <group group_id="P2">
          <title>Lenalidomide 5 mg</title>
          <description>Lenalidomide 5 mg daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Lenalidomide 10 mg</title>
          <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
        </group>
        <group group_id="P4">
          <title>Placebo Crossover to 5 mg Open-label Period</title>
          <description>Participants receiving placebo in the Double-Blind phase and Lenalidomide in the Open-Label phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="42">'Started' includes 23 participants who completed double-blind and 19 who discontinued double-blind.</participants>
                <participants group_id="P3" count="47">'Started' includes 39 participants who completed double-blind and 8 who discontinued double-blind.</participants>
                <participants group_id="P4" count="56">'Started' includes 1 participant who completed double-blind and 55 who discontinued double-blind.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Therapeutic Effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matching to active study arms.</description>
        </group>
        <group group_id="B2">
          <title>Lenalidomide 5 mg</title>
          <description>Lenalidomide 5 mg daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Lenalidomide 10 mg</title>
          <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" lower_limit="39.0" upper_limit="85.0"/>
                    <measurement group_id="B2" value="66.0" lower_limit="40.0" upper_limit="86.0"/>
                    <measurement group_id="B3" value="68.0" lower_limit="36.0" upper_limit="84.0"/>
                    <measurement group_id="B4" value="68.0" lower_limit="36.0" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>5q- (31-33) Chromosomal Abnormality</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Prognostic Scoring System (IPSS)</title>
          <description>The international prognostic scoring system (IPSS) is a standard for risk assessment in primary myelodysplastic syndromes (MDS) that categorizes prognoses taking into account cytogenetics, cytopenias, blasts and blood counts. The IPSS prognostic subgroups consist of low-, intermediate-1-, intermediate-2-, and high-risk groups. The scale is 0-3.5 at 0.5 increments. Scores of 0=Low; 0.5-1.0=Int-1; 1.5-2.0=Int-2; 2.5-3.5=High risk which corresponds to poorer prognosis. The assessment was performed by the Central Reviewer.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low risk (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate-1 (0.5 - 1.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate-2 (1.5 - 2.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk (≥ 2.5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>French-American-British (FAB) Classification</title>
          <description>FAB is a classification system for five (5) subtypes of myelodysplastic syndrome that are distinguished by the percentage of myeloblasts, presence or absence of ringed sideroblasts or a monocytosis. Classification was made by the Central Reviewer.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Refractory anemia (RA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory anemia with ringed sideroblasts (RARS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory anemia with excess blasts (RAEB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic myelomonocytic leukemia (CMML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAEB in transformation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic myelogenous leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specimen not adequate from diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other or missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for &gt;= 26 Weeks (182 Days)</title>
        <description>The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for &gt;= 26 Weeks (182 Days)</title>
          <description>The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.</description>
          <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To compare the response rates of Lenalidomide 5 mg QD vs. placebo, the Hochberg procedure was used to control the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus &gt;0) to compare lenalidomide treatment with placebo.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To compare the response rates of Lenalidomide 10 mg QD vs. placebo, the Hochberg procedure was used to control the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus &gt;0) to compare lenalidomide treatment with placebo.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days</title>
        <description>Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days</title>
          <description>Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.</description>
          <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus &gt;0) to compare lenalidomide treatment with placebo.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus &gt;0) to compare lenalidomide treatment with placebo.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days</title>
        <description>Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.</description>
        <time_frame>up to 3 years</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants who achieved RBC transfusion independence for at least 182 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days</title>
          <description>Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.</description>
          <population>The modified intent-to-treat (mITT) population included all participants who achieved RBC transfusion independence for at least 182 days.</population>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="10.93"/>
                    <measurement group_id="O2" value="107.7" spread="52.35"/>
                    <measurement group_id="O3" value="108.6" spread="40.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days</title>
        <description>For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.</description>
        <time_frame>Baseline, up to 52 weeks</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. MITT participants who were transfusion independent for &gt;= 182 study days are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days</title>
          <description>For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.</description>
          <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. MITT participants who were transfusion independent for &gt;= 182 study days are included.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.61"/>
                    <measurement group_id="O2" value="5.5" spread="1.79"/>
                    <measurement group_id="O3" value="6.0" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
        <description>The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of &lt;100,000/mm^3 as an absolute increase of ≥30,000/mm^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm^3 but less than 30,000/mm^3.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Additionally, the participant must have had a baseline platelet count of &lt;100,000/mm^3 to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
          <description>The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of &lt;100,000/mm^3 as an absolute increase of ≥30,000/mm^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm^3 but less than 30,000/mm^3.</description>
          <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Additionally, the participant must have had a baseline platelet count of &lt;100,000/mm^3 to be included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
        <description>A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase &lt;500/mm^3.</description>
        <time_frame>up to week 52</time_frame>
        <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Additionally, the participant must have had a baseline absolute neutrophil counts (ANC) &lt; 1,000/mm^3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
          <description>A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase &lt;500/mm^3.</description>
          <population>The modified intent-to-treat (mITT) population included all participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Additionally, the participant must have had a baseline absolute neutrophil counts (ANC) &lt; 1,000/mm^3.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
        <description>The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) &lt;5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with &lt;5% blasts pretreatment with an on study blast increase of 50% which is now &gt;5% showed bone marrow progression.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Intent to treat population. Participants represented in the treatment groups to which they were randomized. Placebo response is limited to the double-blind phase. There were 10 responders in the placebo group who achieved their response under lenalidomide treatment after crossover to open-label.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period</title>
          <description>The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) &lt;5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with &lt;5% blasts pretreatment with an on study blast increase of 50% which is now &gt;5% showed bone marrow progression.</description>
          <population>Intent to treat population. Participants represented in the treatment groups to which they were randomized. Placebo response is limited to the double-blind phase. There were 10 responders in the placebo group who achieved their response under lenalidomide treatment after crossover to open-label.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review</title>
        <description>The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Modified intent to treat population, which is defined as participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Participants had to have had more than 1 post-baseline assessment in order to be evaluable for cytogenetic response.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review</title>
          <description>The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.</description>
          <population>Modified intent to treat population, which is defined as participants with centrally-confirmed Low- or Int-1-risk MDS with del 5q[31] and documented RBC transfusion dependence who had received ≥ 1 dose of study drug. Participants had to have had more than 1 post-baseline assessment in order to be evaluable for cytogenetic response.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytogenetic progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable/data not available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study</title>
        <description>Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Intent to treat population. Participants represented in the treatment groups to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study</title>
          <description>Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.</description>
          <population>Intent to treat population. Participants represented in the treatment groups to which they were randomized.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Double-Blind (first 16 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind (52 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind + Open-Label</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimates of Overall Survival by Randomized Group</title>
        <description>Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Safety population: All randomized participants who received any Lenalidomide or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimates of Overall Survival by Randomized Group</title>
          <description>Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.</description>
          <population>Safety population: All randomized participants who received any Lenalidomide or placebo.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="31.9">The confidence interval cannot be estimated due to not enough number of deaths.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="24.6">The confidence interval cannot be estimated due to not enough number of deaths.</measurement>
                    <measurement group_id="O3" value="44.5" lower_limit="35.5">The confidence interval cannot be estimated due to not enough number of deaths.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Count of Deaths During Double-blind and Open-label by Randomized Group</title>
        <description>Count of participant deaths throughout the entire study and reported by the original treatment assignment.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Count of Deaths During Double-blind and Open-label by Randomized Group</title>
          <description>Count of participant deaths throughout the entire study and reported by the original treatment assignment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12</title>
        <description>The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL).
In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants who had both Baseline and Week 12 FACT-An data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12</title>
          <description>The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL).
In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.</description>
          <population>Participants who had both Baseline and Week 12 FACT-An data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="18.50"/>
                    <measurement group_id="O2" value="5.9" spread="18.26"/>
                    <measurement group_id="O3" value="5.8" spread="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12</title>
        <description>The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants who had both Baseline and Week 12 TOI-An data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12</title>
          <description>The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.</description>
          <population>Participants who had both Baseline and Week 12 TOI-An data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="17.13"/>
                    <measurement group_id="O2" value="5.6" spread="15.56"/>
                    <measurement group_id="O3" value="4.9" spread="18.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12</title>
        <description>The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants who had both Baseline and Week 12 TOI-F data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12</title>
          <description>The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.</description>
          <population>Participants who had both Baseline and Week 12 TOI-F data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="14.76"/>
                    <measurement group_id="O2" value="4.8" spread="14.21"/>
                    <measurement group_id="O3" value="3.9" spread="15.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period</title>
        <description>Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
        <time_frame>up to week 52</time_frame>
        <population>Safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching to active study arms.</description>
          </group>
          <group group_id="O2">
            <title>Lenalidomide 5 mg</title>
            <description>Lenalidomide 5 mg daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Lenalidomide 10 mg</title>
            <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period</title>
          <description>Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
          <population>Safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NCI CTCAE grade 3-4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one related NCI CTCAE grade 3-4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one serious AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>An AE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>An AE leading to dose reduction or interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths within 30 days of last dose of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Placebo arm is limited to the double-blind period. Lenalidomide 5 mg and 10 mg treatment arms cover both double-blind and open-label periods. The Placebo Crossover to 5 mg Open-label Period arm is limited to the open-label period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matching to active study arms.</description>
        </group>
        <group group_id="E2">
          <title>Lenalidomide 5 mg</title>
          <description>Lenalidomide 5 mg daily for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Lenalidomide 10 mg</title>
          <description>Lenalidomide 10 mg daily for 21 of 28 days</description>
        </group>
        <group group_id="E4">
          <title>Placebo Crossover to 5 mg Open-label Period</title>
          <description>Participants receiving placebo in the Double-Blind phase and Lenalidomide in the Open-Label phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Amaemia Haemolytic Autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Autoimmune Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cytogenetic Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tooth Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Synovial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urine Human Chorionic Gonadotropin Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Joint Range of Motion Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Acute Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Histiocytosis Haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Refractory Anaemia with an excess of blasts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Cotard's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Mood Altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Stress Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma Gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Iron Overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Multicenter publication must include input from investigators and Celgene, agreement to be established before publication. It has priority over subset (single center) publication, for duration of 1 year after study completion.
Individual investigators have publication right after multicenter publication is complete (or 1 year after study completion), whichever is first. In this case, Celgene has the right to comment and right to ask delay of publication for 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Trials Disclosure</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>1-888-260-1599</phone>
      <email>clinicaltrialdisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

